Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

Nicotinamide riboside

  Cat. No.:  DC32224   Featured
Chemical Structure
1341-23-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Nicotinamide riboside, also known as NR and SRT647, is a pyridine-nucleoside form of vitamin B3 that functions as a precursor to nicotinamide adenine dinucleotide or NAD+. NR blocks degeneration of surgically severed dorsal root ganglion neurons ex vivo and protects against noise-induced hearing loss in living mice. Nicotinamide riboside prevents muscle, neural and melanocyte stem cell senescence. Increased muscular regeneration in mice has been observed after treatment with nicotinamide riboside, leading to speculation that it might improve regeneration of organs such as the liver, kidney, and heart. Nicotinamide riboside also lowers blood glucose and fatty liver in prediabetic and type 2 diabetic models while preventing the development of diabetic peripheral neuropathy. Note: Nicotinamide Riboside chloride is a α/β mixture
Cas No.: 1341-23-7
Chemical Name: Nicotinamide riboside
Synonyms: Nicotinamide ribose;N-ribosylnicotinamid;3-(Aminocarbonyl)-1beta-D-ribofuranosylpyridinium;1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridine-5-carboxamide;Nicotinamide riboside-oxidized form;NRH-oxidized form;Nicotinamide ribonucleoside;NICOTINAMIDE RIBOSIDE;Nicotiamide Riboside;N-ribosylnicotinamide;NR(Nicotinamide Riboside);nicotinamide-beta-riboside;ribosylnicotinamide;1-(beta-D-Ribofuranosyl)nicotinamide;0I8H2M0L7N;Pyridinium, 3-(aminocarbonyl)-1-beta-D-ribofuranosyl-;3-carbamoyl-1-beta-D-ribofuranosylpyridinium;3-Carbamoyl-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridin-1-ium;SRT647;SRT 647;N-ribosyl-nicotinamide;beta-nicotinamide D-ribosi;Nicotinamide riboside chloride;Q3334152;C03150;DTXSID501010039;DB14933;1-b-D-ribosyl-3-Pyridinecarboxamide;nicotinamide riboside;3-(aminocarbonyl)-1-beta-delta-ribofuranosyl-Pyridinium;1-(beta-D ribofuranosyl)nicotinamide;AM84366;CHEMBL438497;UNII-0I8H2M0L7N;1-beta-delta-ribosyl-3-Pyridinecarboxamide;BETA-nicotinamide ribose;Beta-Nicotinamide Riboside;Niagen;SRT-647;SCHEMBL938611;NICOTINAMIDE RIBOSIDE [WHO-DD];3-(aminocarbonyl)-1-beta-d-ribofuranosylpyridinium;Pyridinium, 3-(aminocarbonyl)-1-.beta.-D-ribofuranosyl-;CS-0080934;HY-123033;3-(aminocarbonyl)-1-beta-D-ribofuranosyl-Pyridinium;nicotinamide ribonucleoside;1341-23-7;CHEBI:15927;TruNiagen;AKOS040740858;1-beta-D-ribosyl-3-Pyridinecarboxamide;nicotinamide ribose;3-carbamoyl-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1$l^{5}-pyridin-1-ylium;beta-nicotinamide D-riboside;1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;Nicotinamide Ribose;Nicotinamide Riboside 99%;3-(AMinocarbonyl)-1beta-D-ribofuranosylpyridiniuM
SMILES: O1[C@]([H])(C([H])([H])O[H])[C@]([H])([C@]([H])([C@]1([H])[N+]1=C([H])C([H])=C([H])C(C(N([H])[H])=O)=C1[H])O[H])O[H]
Formula: C11H15N2O5
M.Wt: 255.2472
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Nicotinamide riboside is a crystal form of Nicotinamide riboside (NR) chloride. Nicotinamide riboside increases NAD[+] levels and activates SIRT1 and SIRT3, culminating in enhanced oxidative metabolism and protection against high fat diet-induced metabolic abnormalities. Nicotinamide riboside is used in dietary supplements[1].
Target: SIRT1 SIRT3
In Vivo: Chronic Nicotinamide riboside (p.o.; 400 mg/kg/day; for 16 weeks) supplementation increases plasma and intracellular NAD[+] content in a tissue-specific manner[1]. Animal Model: 10-week-old C57Bl/6J mice[1] Dosage: 400 mg/kg Administration: p.o.; daily; for 16 weeks Result: Increased plasma and intracellular NAD[+] content in a tissue-specific manner.
In Vitro: Nicotinamide riboside (0.5 nM; 24 hours) reduces the acetylation status of Ndufa9 and SOD2[1]. Western Blot Analysis[1] Cell Line: HEK293T cells Concentration: 0.5 nM Incubation Time: 24 hours Result: Reduced the acetylation status of Ndufa9 and SOD2.
References: [1]. Cantó C, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protectsagainst high-fat diet-induced obesity. Cell Metab. 2012 Jun 6;15(6):838-47.
MSDS
TITLE DOWNLOAD
MSDS_14536_DC32224_23111-00-4
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC31074 Isopropyl myristate Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868 AZ14133346 AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865 TI17 ​​TI17​​ represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816 Nisoxetine Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641 GENZ-644282 TFA salt Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325 PSMA-617 TFA PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202 Fosaprepitant free acid Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748 O4I4 O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684 ZH8667 ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646 EB-PSMA-617 EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.
X